Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
Tyverb(R)/Tykerb(R) Plus Letrozole Significantly Delayed Disease Progression In Post-menopausal Women With ErbB2 Positive Metastatic Breast Cancer
http://www.medicalnewstoday.com/articles/132882.php
New results from a study in metastatic breast cancer showed that the combination of Tyverb®/Tykerb® (lapatinib) plus letrozole as a first line treatment regimen provided a significant improvement in delaying disease progression when compared to treatment with Femara® (letrozole) alone.
Breast Cancer Drugs In The Pipeline
http://www.medicalnewstoday.com/articles/132869.php
Scientists in the clinic and the laboratory continue to work to drive breast cancer mortality rates down with breakthrough drugs. With tamoxifen's discovery 30 years behind us, and the impact of Herceptin still being felt, researchers are studying zoledronic acid, aromatase inhibitors and monoclonal antibodies, among others, with encouraging results.
New Data Shows Zometa(R) Enhances Impact Of Chemotherapy On Reducing Breast Tumour Size
http://www.medicalnewstoday.com/articles/132855.php
New data released today demonstrates that the addition of Zometa(R) (zoledronic acid) infusion to standard chemotherapy before breast cancer surgery reduces the size of breast tumours more effectively than chemotherapy alone in women with early-stage disease.
Women With Metastatic Breast Cancer Can Benefit From Estrogen Pills
http://www.medicalnewstoday.com/articles/132854.php
For breast cancer survivors, the idea of taking estrogen pills is almost a taboo. In fact, their doctors give them drugs to get rid of the hormone because it can fuel the growth of breast cancer.
Tamoxifen's Power Comes From Endoxifen, Mayo Clinic Researchers Find
http://www.medicalnewstoday.com/articles/132836.php
Mayo Clinic researchers have discovered that a chemical known as endoxifen appears to be the primary metabolite responsible for the effectiveness of tamoxifen in treating breast cancer, and that it works against cancer in an entirely unexpected way.
Age-Related Breast Cancer Rates Differ Among Black, White Women, Study Finds
http://www.medicalnewstoday.com/articles/132803.php
Black women have higher rates of early-onset breast cancer and lower rates of late-onset breast cancer than their white counterparts, according to a study published in the December <cite>Journal of the National Cancer Institute</cite>, <a href="http://www.
Study Adds To Evidence That Age-Related Breast Cancer Rates Differ Among Racial Groups
http://www.medicalnewstoday.com/articles/132781.php
White women have lower rates of early-onset breast cancer and higher rates of late-onset breast cancer compared with black women, according to a <A href="http://jnci.oxfordjournals.org/cgi/content/full/djn411" target=_new>study</A> published in the <CITE>Journal of the National Cancer Institute</CITE>, <A href="http://www.
Femara 1st Aromatase Inhibitor To Indicate Overall Survival Benefit Versus Tamoxifen When Taken For Five Years After Breast Cancer Surgery
http://www.medicalnewstoday.com/articles/132767.php
Femara showed reduced risk of death by 13% (P=0.08) versus tamoxifen, despite inclusion of patients who had switched over from tamoxifen to Femara during the study period, following the study's unblinding - In a separate censored analysis excluding patients after they crossed over to Femara, reduction in risk of death was 19% (HR= 0.
Zoledronic Acid With Neoadjuvant Chemotherapy May Boost Pathological Response In Breast Cancer Patients
http://www.medicalnewstoday.com/articles/132761.php
SAN ANTONIO - New data suggest that adjuvant treatment with the bisphosphonate zoledronic acid (<a href="http://www.zometa.com" target="_blank" rel="nofollow">Zometa</a>) plus chemotherapy may have a direct anti-tumor effect in women with breast cancer who are at high risk of a relapse.
Tamoxifen's Power Comes From Endoxifen, Which They Say Could Potentially Be Turned Into A Breast Cancer Drug
http://www.medicalnewstoday.com/articles/132753.php
Mayo Clinic researchers have discovered that a chemical known as endoxifen appears to be the primary metabolite responsible for the effectiveness of tamoxifen in treating breast cancer, and that it works against cancer in an entirely unexpected way.
Meta Analyses Of Global Trials Finds In Favor Of Aromatase Inhibitors
http://www.medicalnewstoday.com/articles/132746.php
Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back.
New Data Show Zometa(R) Enhances Impact Of Chemotherapy On Reducing Breast Tumor Size
http://www.medicalnewstoday.com/articles/132734.php
New data released demonstrate that the addition of Zometa(R) (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease.
Easton Honored With Inaugural AACR Outstanding Investigator Award In Breast Cancer Research
http://www.medicalnewstoday.com/articles/132730.php
Douglas Easton, Ph.D., whose international studies in breast cancer explained the genetic patterns and causes of the BRCA1 and BRCA2 gene mutations which indicate a person's risk for breast cancer, has been selected to receive the inaugural American Association for Cancer Research (AACR) Outstanding Investigator Award in Breast Cancer Research.
Breast Cancer - AstraZeneca's Response To Letrozole Datapresented At San Antonio Breast Cancer Symposium (SABCS), 11 -14 December 2008
http://www.medicalnewstoday.com/articles/132727.php
AstraZeneca is pleased to see additional data presented at SABCS reinforce that there is no evidence that a sequencing strategy is superior to a 5 year aromatase inhibitor (AIs) strategy. AstraZeneca believes that AIs should be used upfront in all newly diagnosed breast cancer postmenopausal women as it is critical to keep patients cancer free for as long as possible.
----------------------------------------------
** CANCER / ONCOLOGY News **
GTCbio Announces Its 2nd Annual Oncology Biomarkers Conference
http://www.medicalnewstoday.com/articles/132868.php
GTCbio just announced its 2nd Annual Oncology Biomarkers Conference taking place on January 19-20, 2009 in Miami, Florida.The conference will take attendees through "The Life Cycle of a Cancer Biomarker"; examining the path from the identification of a candidate biomarker, development through validation, onto the clinic to be able to identify unmet needs and spark new discoveries back in the laboratory.
Samir Hanash To Give Keynote Speech At GTCbio's 2nd Oncology Biomarkers Conference On January 19-20, 2009 In Miami, Florida
http://www.medicalnewstoday.com/articles/132867.php
Dr. Samir Hanash, Program Head at the Fred Hutchinson Cancer Research Center in Seattle, WA will give the keynote address on the discovery and development of biomarkers at the 2nd annual Oncology Biomarkers Conference on January 19-20, 2009 in Miami, Florida.
New Data Shows Zometa(R) Enhances Impact Of Chemotherapy On Reducing Breast Tumour Size
http://www.medicalnewstoday.com/articles/132855.php
New data released today demonstrates that the addition of Zometa(R) (zoledronic acid) infusion to standard chemotherapy before breast cancer surgery reduces the size of breast tumours more effectively than chemotherapy alone in women with early-stage disease.
Viralytics Positive Pre-clinical Research Results On CAVATAKTM In Human Brain Cancer
http://www.medicalnewstoday.com/articles/132849.php
Viralytics Limited (ASX:VLA) Researchers from the University of Newcastle and Viralytics Limited have demonstrated the first step to "proof of concept" with the destruction of human brain tumours by CAVATAKTM , Viralytics' lead product.
Zoledronic Acid With Neoadjuvant Chemotherapy May Boost Pathological Response In Breast Cancer Patients
http://www.medicalnewstoday.com/articles/132761.php
SAN ANTONIO - New data suggest that adjuvant treatment with the bisphosphonate zoledronic acid (<a href="http://www.zometa.com" target="_blank" rel="nofollow">Zometa</a>) plus chemotherapy may have a direct anti-tumor effect in women with breast cancer who are at high risk of a relapse.
Researcher Invents Lethal 'Lint Brush' To Capture And Kill Cancer Cells In The Bloodstream
http://www.medicalnewstoday.com/articles/132747.php
In a new tactic in the fight against cancer, Cornell University researcher Michael King has developed what he calls a lethal "lint brush" for the blood -- a tiny, implantable device that captures and kills cancer cells in the bloodstream before they spread through the body.
Enrollment In Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
http://www.medicalnewstoday.com/articles/132738.php
Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary Percutaneous Hepatic Perfusion ("PHP") System for the treatment of cancers of the liver, announced today that the first fifty percent (46 of 92) of patients have been enrolled in the Phase III clinical trial treating metastatic cutaneous and ocular melanoma to the liver.
Easton Honored With Inaugural AACR Outstanding Investigator Award In Breast Cancer Research
http://www.medicalnewstoday.com/articles/132730.php
Douglas Easton, Ph.D., whose international studies in breast cancer explained the genetic patterns and causes of the BRCA1 and BRCA2 gene mutations which indicate a person's risk for breast cancer, has been selected to receive the inaugural American Association for Cancer Research (AACR) Outstanding Investigator Award in Breast Cancer Research.
Breast Cancer - AstraZeneca's Response To Letrozole Datapresented At San Antonio Breast Cancer Symposium (SABCS), 11 -14 December 2008
http://www.medicalnewstoday.com/articles/132727.php
AstraZeneca is pleased to see additional data presented at SABCS reinforce that there is no evidence that a sequencing strategy is superior to a 5 year aromatase inhibitor (AIs) strategy. AstraZeneca believes that AIs should be used upfront in all newly diagnosed breast cancer postmenopausal women as it is critical to keep patients cancer free for as long as possible.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
January Is Cervical Health Awareness Month
http://www.medicalnewstoday.com/articles/132751.php
According to the American Cancer Society, 3,870 mothers, daughters, and wives will die from cervical cancer in 2008. Over 11,000 new cases of cervical cancer will be diagnosed by year's end. The Cancer Institute of New Jersey (CINJ) is making experts available to discuss risk factors, treatment and prevention options surrounding cervical cancer.
----------------------------------------------
** COLORECTAL CANCER News **
No news for this category today.
----------------------------------------------
** LUNG CANCER News **
NM Tech, Biomoda Win Legislative Support For Lung Cancer Screening
http://www.medicalnewstoday.com/articles/132759.php
The New Mexico State Legislature's Interim Tobacco Settlement Committee has recommended $730,000 in funding to continue a pilot program to screen veterans for early-stage lung cancer. The request in favor of the clinical study administered by the New Mexico Department of Veterans Services (NMDVS) came from the New Mexico Institute of Mining and Technology (NM Tech) and Biomoda, Inc.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
Promising Results From Two Trials Highlighting Developmental Oral IMiDS(R) Compound Pomalidomide Presented At The ASH
http://www.medicalnewstoday.com/articles/132881.php
Celgene International Sarl (Nasdaq: CELG) today announced that its next IMiDs compound, pomalidomide, has shown promising activity with manageable safety and tolerability for the treatment of relapsed/refractory multiple myeloma (MM) and myelofibrosis.
Clinical Trial Focuses On New Drug For Solid Cancer Tumors And NHL
http://www.medicalnewstoday.com/articles/132752.php
Researchers at The Cancer Institute of New Jersey (CINJ) have opened a clinical trial, which aims to evaluate a new treatment for solid cancer tumors and non-Hodgkin's lymphoma (NHL) in combination with a chemotherapy agent called cyclophosphamide.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
No news for this category today.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment